Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Atrial Fibrillation Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Atrial Fibrillation Overview | 10 | 1 |
| Pipeline Products for Atrial Fibrillation Comparative Analysis | 11 | 1 |
| Atrial Fibrillation Therapeutics under Development by Companies | 12 | 1 |
| Atrial Fibrillation Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Atrial Fibrillation Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Atrial Fibrillation Products under Development by Companies | 17 | 2 |
| Atrial Fibrillation Products under Investigation by Universities/Institutes | 19 | 1 |
| Atrial Fibrillation Companies Involved in Therapeutics Development | 20 | 12 |
| ARCA biopharma, Inc. | 20 | 1 |
| AstraZeneca Plc | 21 | 1 |
| Bristol-Myers Squibb Company | 22 | 1 |
| Cardiome Pharma Corp. | 23 | 1 |
| Daiichi Sankyo Company, Limited | 24 | 1 |
| Dong-A Socio Holdings Co. Ltd. | 25 | 1 |
| Gilead Sciences, Inc. | 26 | 1 |
| Laboratoires Pierre Fabre SA | 27 | 1 |
| Nissan Chemical Industries, Ltd. | 28 | 1 |
| OMEICOS Therapeutics GmbH | 29 | 1 |
| Otsuka Holdings Co., Ltd. | 30 | 1 |
| Xention Limited | 31 | 1 |
| Atrial Fibrillation Therapeutics Assessment | 32 | 9 |
| Assessment by Monotherapy Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 37 |
| AFC-1 Drug Profile | 41 | 1 |
| BMS-919373 Drug Profile | 42 | 1 |
| bucindolol hydrochloride Drug Profile | 43 | 7 |
| edoxaban tosylate Drug Profile | 50 | 5 |
| F-373280 Drug Profile | 55 | 1 |
| flecainide acetate Drug Profile | 56 | 1 |
| Gene Therapy for Atrial Fibrillation Drug Profile | 57 | 1 |
| GS-967 Drug Profile | 58 | 1 |
| NIP-151 Drug Profile | 59 | 2 |
| OMT-28 Drug Profile | 61 | 1 |
| OPC-108459 Drug Profile | 62 | 1 |
| Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation Drug Profile | 63 | 1 |
| Small Molecule to Block Kv1.5 for Atrial Fibrillation Drug Profile | 64 | 1 |
| Small Molecules to Block GIRK for Atrial Fibrillation Drug Profile | 65 | 1 |
| Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation Drug Profile | 66 | 1 |
| Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure Drug Profile | 67 | 1 |
| STP-023725 Drug Profile | 68 | 1 |
| vernakalant hydrochloride Drug Profile | 69 | 4 |
| XEN-R0702 Drug Profile | 73 | 1 |
| XEND-0103 Drug Profile | 74 | 2 |
| XENR-0703 Drug Profile | 76 | 1 |
| XENR-0706 Drug Profile | 77 | 1 |
| Atrial Fibrillation Dormant Projects | 78 | 5 |
| Atrial Fibrillation Discontinued Products | 83 | 1 |
| Atrial Fibrillation Product Development Milestones | 84 | 12 |
| Featured News &Press Releases | 84 | 1 |
| May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study | 84 | 1 |
| May 02, 2016: New drug more effective in treating atrial fibrillation | 84 | 1 |
| Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation | 85 | 1 |
| Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session | 85 | 2 |
| Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA | 87 | 1 |
| Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia | 87 | 1 |
| Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant | 87 | 1 |
| Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015 | 88 | 1 |
| Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation | 89 | 1 |
| Sep 23, 2015: UK s NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation | 89 | 2 |
| Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing | 91 | 1 |
| Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China | 91 | 1 |
| Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice" | 91 | 2 |
| Jun 25, 2015: Daiichi Sankyo s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE | 93 | 1 |
| Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation | 94 | 2 |
| Appendix | 96 | 2 |
| Methodology | 96 | 1 |
| Coverage | 96 | 1 |
| Secondary Research | 96 | 1 |
| Primary Research | 96 | 1 |
| Expert Panel Validation | 96 | 1 |
| Contact Us | 96 | 1 |
| Disclaimer | 97 | 1 |